



Crescendo broadens patent protection in US on VH-producing lambda chain KO mice

Cambridge, UK, 25 April 2019 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody® therapeutics, has been granted US patent No. 10,194,645 for its novel transgenic mouse platform for generating Humabody® drug products.

The patent covers knock out mice which do not produce functional endogenous antibody lambda light chains due to specific deletions in the lambda light chain locus. The broad scope of granted claims of this US patent is nearly identical to the IP protection of Crescendo's proprietary triple KO-mouse in Europe.

-Ends-

For more information, please contact:

Crescendo Biologics

+ 44 (0)1223 497140

info@crescendobiologics.com

Instinctif Partners

Melanie Toyne-Sewell, Dr Christelle Kerouedan, Deborah Bell

+ 44 (0)20 7457 2020

crescendo@instinctif.com

About Crescendo Biologics

Crescendo Biologics is a T-cell enhancing company. Crescendo develops potent, truly differentiated Humabody® therapeutics with a focus on innovative, targeted T-cell approaches in oncology.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel CD137-PSMA bispecific for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment – avoiding systemic toxicity.

The Company's ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® V_H). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit the website: www.crescendobiologics.com.